特异性泛素蛋白酶22在急性白血病细胞中的表达及其临床意义  

Expression of USP22 in Patients with Acute Leukemia and Its Clinical Signifi cance

作　　者：徐志阳 田文亮[1] 付雪[1] 汤平[1] 陈丹丹[1] 王芳[1] 陈绍倩[1] 孟小莉[1] 刘林湘[1] 孙玲[1] 

机构地区：[1]郑州大学第一附属医院血液科,郑州450052

出　　处：《肿瘤防治研究》2014年第4期366-369,共4页Cancer Research on Prevention and Treatment

摘　　要：目的探讨特异性泛素蛋白酶22(USP22)在急性白血病(AL)细胞中的表达及其临床意义。方法采用荧光定量PCR及Western blot检测USP22基因及蛋白在Jurkat、HL-60、K562、molt-4和NB4细胞系、急性白血病患者及阴性对照者骨髓单个核细胞中的表达量情况。结果 USP22在Jurkat、HL-60、K562、molt-4和NB4细胞系均有所表达。USP22 mRNA在急性白血病患者初诊组(33.90±9.58)、缓解组(1.81±0.53)中的表达量与阴性对照组(1.05±0.33)相比均上调,USP22蛋白在急性白血病患者初诊组(0.58±0.15)、缓解组(0.10±0.03)中的表达量与阴性对照组(0.05±0.02)相比均上调,差异均具有统计学意义(P<0.001);其中USP22 mRNA在初诊组高白细胞AL患者中的表达量(45.23±10.92)高于非高白细胞患者(26.73±6.12),USP22蛋白在初诊组高白细胞急性白血病患者中的表达量(0.69±0.16)高于非高白细胞患者(0.42±0.10),差异均具有统计学意义(P<0.001)。但USP22基因和蛋白在初诊组急性髓系白血病(AML)与急性淋巴细胞白血病(ALL)患者间的表达差异无统计学意义(P=0.531,0.377),并且本研究对急性白血病患者的临床转归进行了观察,与低表达USP22的急性白血病患者初次诱导缓解率(88.0%)相比,高表达的缓解率(66.67%)较低。结论 USP22在急性白血病中表达率较高,它的表达水平可能与白细胞数目有关,USP22可作为判断急性白血病患者预后的标志基因之一。Objective To investigate the expression of ubiquitin-specifi c protease 22(USP22) in bone marrow cells in patients with acute leukemia(AL) and its clinical signifi cance. Methods Real-time quantitative PCR(qPCR) and Western blot were used to detect mRNA and protein expression levels of USP22 in Jurkat, HL-60, K562, molt-4 and NB4 cell lines and bone marrow mononuclear cells from AL patients and negative control patients, respectively. Results USP22 expression was found in Jurkat, HL-60, K562, molt-4 and NB4 cell lines. mRNA and protein expressions of USP22 in initial diagnosis group(33.90±9.58) and(0.58±0.15) and remission group(1.81±0.53) and(0.10±0.03) were both increased, compared with that in negative control group(1.05±0.33) and(0.05±0.02)(P<0.001). Meanwhile, expression levels of USP22 mRNA and protein in hyperleukocytic AL patients in initial diagnosis group(45.23±10.92) and(0.69±0.16) were significantly higher than those in non-hyperleukocytic AL patients [(26.73±6.12) and(0.42±0.10), P<0.001]. But no signifi cant difference of USP22 and protein expressions was found between acute myeloid leukemia(AML) and acute lymphoblastic leukemia(ALL) patients in initial diagnosis group(P=0.531, 0.377). Moreover, AL patients with higher USP22 expression(66.67%) had lower complete remission rate than that with lower USP22 expression(88.0%) after the fi rst induction chemotherapy. Conclusion USP22 is highly expressed in AL patients and decreased after complete remission, which might relate to leukocytes number. Taken together, it could be a useful parameter for prognosis of AL patients.

关 键 词：特异性泛素蛋白酶22 急性白血病 肿瘤干细胞 预后 

分 类 号：R733.71[医药卫生—肿瘤]